4.5 Review

Interleukin-18, more than a Th1 cytokine

Journal

SEMINARS IN IMMUNOLOGY
Volume 25, Issue 6, Pages 439-448

Publisher

ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
DOI: 10.1016/j.smim.2013.10.014

Keywords

-

Categories

Funding

  1. NIH [AI-15614, AR-45584, CA-04 6934]
  2. Agence Nationale de la Recherche-Maladies Rares et Projet National de Recherche Clinique
  3. National Research Foundation of Korea (MEST) [2012R1A2A1A01001791]
  4. Konkuk University
  5. National Research Foundation of Korea [2012R1A2A1A01001791] Funding Source: Korea Institute of Science & Technology Information (KISTI), National Science & Technology Information Service (NTIS)

Ask authors/readers for more resources

Together with IL-12 or IL-15, interleukin-18 (IL-18) plays a major role in the production of interferon-gamma from T-cells and natural killer cells; thus, IL-18 is considered to have a major role in the Th1 response. However, without IL-12, IL-18 is proinflammatory in an IFN gamma independent manner. IL-18 is a member of the IL-1 family of cytokines and similar to IL-1 beta, the cytokine is synthesized as an inactive precursor requiring processing by caspase-1 into an active cytokine. IL-18 is also present as an integral membrane protein but requires caspase-1 for full activity in order to induce IFN gamma. Uniquely, unlike IL-1 beta, the IL-18 precursor is constitutively present in nearly all cells in healthy humans and animals. The activity of IL-18 is balanced by the presence of a high-affinity, naturally occurring IL-18 binding protein (IL-18BP). In humans, increased disease severity can be associated with an imbalance of IL-18 to IL-18BP such that the levels of free IL-18 are elevated in the circulation. Increasing number of studies have expanded the role of IL-18 in mediating inflammation in animal models of disease using the IL-18BP, IL-18 deficient mice, neutralization of IL-18 or deficiency in the IL-18 receptor alpha chain. A role for IL-18 has been implicated in several autoimmune diseases, myocardial function, emphysema, metabolic syndromes, psoriasis, inflammatory bowel disease, macrophage activation syndrome, sepsis and acute kidney injury, although paradoxically, in some models of disease, IL-18 is protective. The IL-18BP has been used safely in humans and clinical trials of IL-18BP as well as neutralizing anti-IL-18 antibodies are being tested in various diseases. (C) 2013 Elsevier Ltd. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available